Wall Street Zen Downgrades BioNTech (NASDAQ:BNTX) to Sell

BioNTech (NASDAQ:BNTX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other analysts have also weighed in on BNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. The Goldman Sachs Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $171.00 target price on shares of BioNTech in a report on Wednesday, March 11th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.73.

BioNTech Stock Performance

NASDAQ BNTX opened at $91.19 on Friday. The business has a 50 day moving average price of $106.43 and a 200 day moving average price of $102.54. The company has a market capitalization of $21.88 billion, a P/E ratio of -17.40 and a beta of 1.51. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its position in BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC purchased a new position in BioNTech in the 1st quarter valued at about $167,000. Envestnet Asset Management Inc. boosted its stake in shares of BioNTech by 20.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company’s stock worth $1,125,000 after purchasing an additional 1,808 shares during the last quarter. Allworth Financial LP grew its holdings in shares of BioNTech by 1,176.8% during the second quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock worth $129,000 after buying an additional 1,118 shares in the last quarter. Finally, SBI Securities Co. Ltd. grew its holdings in shares of BioNTech by 5.2% during the second quarter. SBI Securities Co. Ltd. now owns 3,865 shares of the company’s stock worth $412,000 after buying an additional 192 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.